NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Valneva SE VALN
7 fiscal years on record · EUR · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
€174.7M
▲ 3.0% vs FY2024
EPS · FY25
€-0.68
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-66.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 174.7M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 66 cents on every revenue dollar this year.
Per share
EUR -0.68
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-47.0%
Net margin-66.0%
Return on assets-25.6%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+9.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−21.5%
+9.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.17B
Shares outstanding, FY2025
Change, 5 years+90.9%
Change, 10 years—
The share count grew 91% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 398.8M
total assets, end of FY2025
Total assetsEUR 398.8M
CashEUR 109.7M
Gross debtEUR 179.2M
Net debtEUR 69.5M
Current ratio2.38×
History
7 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue €B
0.2
0.2
0.2
0.4
0.3
0.1
0.1
Operating income €B
−0.1
0.0
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA €B
−0.1
0.0
−0.1
−0.1
−0.0
−0.0
·
Income tax €B
0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
Net income €B
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted €
−0.68
−0.08
−0.73
−1.24
−0.75
−0.71
−0.02
Dividend / sh €
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
Shares out B
0.17
0.16
0.14
0.14
0.11
0.09
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
19 of 19
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed